HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
4.240
-0.390 (-8.42%)
At close: Sep 5, 2025, 4:00 PM
4.390
+0.150 (3.54%)
After-hours: Sep 5, 2025, 7:48 PM EDT

Company Description

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States.

The company’s lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.

It also develops HCW9201 and HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer.

The company has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules.

HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

HCW Biologics Inc.
HCW Biologics logo
CountryUnited States
Founded2018
IPO DateJul 20, 2021
IndustryBiotechnology
SectorHealthcare
Employees36
CEOHing Wong

Contact Details

Address:
2929 North Commerce Parkway
Miramar, Florida 33025
United States
Phone954 842 2024
Websitehcwbiologics.com

Stock Details

Ticker SymbolHCWB
ExchangeNASDAQ
Stock TypeCommon Stock
Share ClassClass A Shares
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$8.00
CIK Code0001828673
CUSIP Number40423R105
ISIN NumberUS40423R1059
Employer ID82-5024477
SIC Code2834

Key Executives

NamePosition
Dr. Hing C. Wong Ph.D.Founder, Chief Executive Officer, Director and Secretary
Rebecca Byam CPA, M.B.A.Chief Financial Officer
Dr. Peter Rhode Ph.D.Chief Scientific Officer and Vice President of Clinical Operations
Nicole Valdivieso Esq.Vice President of Legal Affairs
Lee D. FlowersSenior Vice President of Business Development

Latest SEC Filings

DateTypeTitle
Sep 5, 20258-KCurrent Report
Aug 19, 20258-KCurrent Report
Aug 18, 202510-QQuarterly Report
Aug 18, 20258-K/A[Amend] Current report
Aug 15, 2025NT 10-QNotification of inability to timely file Form 10-Q or 10-QSB
Aug 15, 20258-KCurrent Report
Aug 14, 20258-KCurrent Report
Jul 18, 20258-KCurrent Report
Jul 1, 20258-KCurrent Report
Jun 26, 20258-KCurrent Report